R&D Trends

GeNeuro, NIH partner to develop novel antibody treatment for ALS

Friday, February 10, 2017

GeNeuro, a biopharmaceutical company developing new treatments for neurological disorders and autoimmune diseases, including multiple sclerosis (MS), has announced the signing of a Cooperative Research and Development Agreement (CRADA) with The National Institute of Neurological Disorders and Stroke (NINDS), part of the NIH, to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis (ALS). The research will evaluate the ability of these antibodies to neutralise a potential causal factor of ALS, the envelope protein of HERV-K (a family of Human Endogenous Retroviruses, HERVs). 

[Read More]

Koch Institute receives $1M from Takeda to support immuno-oncology research

Friday, February 10, 2017

Takeda Pharmaceutical and the Koch Institute for Integrative Cancer Research at MIT jointly announced that Takeda will support groundbreaking science in immuno-oncology at the Koch Institute. Over the next two years, the $1 million gift will help to build upon the research currently being conducted by the Institute to investigate the role of the immune response in cancer and develop potential novel treatments.

[Read More]

NIH to expand critical catalog for genomics research

Monday, February 6, 2017

The NIH plans to expand its Encyclopedia of DNA Elements (ENCODE) Project, a genomics resource used by many scientists to study human health and disease. Funded by the National Human Genome Research Institute (NHGRI), part of NIH, the ENCODE Project is generating a catalog of all the genes and regulatory elements—the parts of the genome that control whether genes are active or not—in humans and select model organisms. With four years of additional support, NHGRI builds on a long-standing commitment to developing freely available genomics resources for use by the scientific community.

[Read More]

All of Us Research Program announces funding opportunity for community partners

Thursday, February 2, 2017

The NIH has announced a new opportunity for organizations interested in helping engage volunteers in the All of Us Research Program, part of the Precision Medicine Initiative. This funding opportunity, open to national and regional organizations, as well as local community groups, will support activities to promote enrollment and retention in the All of Us Research Program across diverse communities.

[Read More]

ESSA Pharma receives $4M from Research Institute of Texas

Wednesday, February 1, 2017

ESSA Pharma, a pharmaceutical company, currently in the clinical development stage, focused on the development of small molecule drugs for the treatment of prostate cancer, announced the receipt of a $4 million payment from the Cancer Prevention Research Institute of Texas (CPRIT). The payment is part of a total non-dilutive grant of $12 million, repayable out of potential product revenues, which was originally awarded in February 29, 2014.

[Read More]